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The development of new anticancer agents derived
from natural resources requires a rapid identification
of their molecular mechanism of action. To make this
step short, we have initiated the proteomic profiling
of HeLa cells treated with anticancer drugs
representing a wide spectrum of mechanisms of
action using two-dimensional difference gel electro-
phoresis (2D-DIGE). Unique proteome patterns were
observed in HeLa cells treated with the HSP90 inhib-
itor geldanamycin, and were similar to the patterns
induced by radicicol, a structurally different HSP90
inhibitor. On the other hand, etoposide and ICRF-
193, compounds claimed to be topoisomerase II
inhibitors, showed different proteomic profiles,
which reflect their different biological activities as
revealed by cell-cycle analysis. Thus far, combined
data from 19 compounds have allowed their
successful classification by cluster analysis accord-
ing to the mechanism of action.
INTRODUCTION
Cell-based assays are widely used in drug discovery because
the assessment of molecular interaction occurs within the
context of a living cellular environment (Baker et al., 2007).
Many bioactive compounds inhibiting the growth of cancer cells
have been isolated using a cell-based screen (Kakeya et al.,
2002; Kawada et al., 2009). In most instances, the molecular
target for newly isolated compounds remains unknown. The
identification of a plausible target is sometimes possible based
on the results of cell-based assays; however, the exact target
must be proven by enzymatic assays, analyses of binding
proteins, or genetic methods employing an siRNA (Kazami
et al., 2006; Sato et al., 2007; Teruya et al., 2005). The
confirmation of molecular targets, however, is usually a difficult
and time-consuming process.
Multidimensional phenotype profiling approaches have
a capacity to generate a testable hypothesis related to the460 Chemistry & Biology 17, 460–470, May 28, 2010 ª2010 Elseviermechanism of action and eventual off-target effects of new
compounds. The differential sensitivity of the panel of cancer
cell lines to the compounds has been used to identify their
molecular target(s). The most commonly used assay, the NCI
60 antitumor screen, allowed the identification of benzolactone
enamide as an inhibitor of V-ATPase (Boyd et al., 2001). Another
panel consisting of 39 different cancer cell lines identified the
compound encoded as ZSTK474 to be an inhibitor of phospha-
tidylinositol 3-kinase (Yaguchi et al., 2006). Recent advances in
the field of molecular biology have provided a wide spectrum
of methods suitable for target identification. The application of
the Connectivity Map, developed by Golub and coworkers,
which uses gene expression signature for profiling (Lamb et al.,
2006), led to the identification of a class of HSP90 pathway
modulators (gedunin and celastrol) (Hieronymus et al., 2006).
Cell morphology-based profiling (Abassi et al., 2009; MacDonald
et al., 2006) and activity-based proteomic profiling (Leung et al.,
2003) are also used for molecular target identification.
Compared with gene expression profiling, which can simulta-
neously measure the expression of more than 20,000 genes,
proteome analysis provides us only with the opportunity to trace
at most 1,000 protein spots. However, any change of molecular
weight and isoelectric point of proteins after posttranslational
modification is often detectable as a mobility shift of protein
spots in two-dimensional gel electrophoresis (2DE) analyses.
Because biologically active compounds affect cellular
processes and induce changes in both expression level and
modification of proteins, proteome profiling is an informative
approach for investigating the effects of a compound. Indeed,
several research groups have shown that a biologically active
compound alters the proteome (Cecconi et al., 2007; Towbin
et al., 2003). Recent advances in two-dimensional difference
gel electrophoresis (2D-DIGE) have allowed the measurement
of the abundance of each protein spot between different gels
with high accuracy due to introduction of an internal standard
(Van den Bergh and Arckens, 2004). With 2D-DIGE, the abun-
dant proteomic expression data obtained from different treat-
ments can be collected and the expression patterns can be
compared. In this study, we have used 2D-DIGE to perform
a comprehensive proteome analysis of protein expression
changes caused by the treatment of cancer cells with anticancer
drugs claimed to possess the exact mechanisms of action.Ltd All rights reserved
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Proteomic Profiling for Compound ClassificationIt is well known that the anticancer drugs of known and similar
mechanisms of action such as doxorubicin and daunorubicin,
both classified as anthracyclines, are clinically active against
different types of cancers. Doxorubicin is mainly used in the
treatment of solid tumors, whereas daunorubicin shows activity
in hematologic malignancies. Another case is cisplatin and oxa-
liplatin, the former active against lung and ovarian cancers and
the latter active against colon cancer. Keeping in mind a subtle
difference in clinical activity of the compounds of similar exact
mechanism of action, we have made an attempt to establish
differential protein profiles in cancer cells treated with anticancer
agents representing several main mechanisms of action,
including also several compounds possessing the same well-es-
tablished mechanism of action. The proteomic profiling of
mechanism of action may play an essential role in the planning
of individualized chemotherapy of cancer patients once the
correlation between drug sensitivity and the drug-induced
proteomic profile is found.
Here we report the procedure and results of the proteome
analysis using 2D-DIGE that revealed significant similarities in
protein expression changes induced by the compounds
belonging to the same class. Furthermore, we were also able
to distinguish subtle differences among compounds attacking
the same molecular target, though in a different way.
RESULTS
Proteomic Patterns of Geldanamycin- and Radicicol-
Treated HeLa Cells Are Similar
Geldanamycin (1) and radicicol (2) are well-known HSP90
inhibitors (Schulte et al., 1998; Whitesell et al., 1994). HSP90 is
a target for cancer therapeutics, and 17-AAG is a derivative of
geldanamycin undergoing clinical trials (Nowakowski et al.,
2006). First, we determined the cell growth inhibitory effect of
HSP90 inhibitors against HeLa cells using a WST-8 assay
(Figure 1A). The 50%growth inhibitory concentration (IC50) of gel-
danamycin against HeLa cells was approximately 0.05 mM in
a 48 hr treatment. HeLa cell growth was not affected at concen-
trations lower than 0.01 mM, whereas complete growth inhibition
was observed at concentrations greater than 0.1 mM. The IC50 of
radicicol against HeLa cell growth was approximately 1 mM.
Next, we investigated the relationship between proteomic
changes after exposing HeLa cells to effective concentrations
of the compounds, 0.005, 0.05, 0.5, 5, and 10 mM for geldanamy-
cin and 10 mM for radicicol; the results are shown in Figure 1B. In
this analysis, 775 spots in 2DE gels were matched on all gel
images and quantified by 2D-DIGE system software, resulting
in 282 spots that were selected by ANOVA (p < 0.01) and Dun-
nett’s test (p < 0.01) (see Table S1 available online). Then, hierar-
chical cluster analysis was performed. The results are displayed
in the form of a heat map and a tree diagram (Figure 1B). In the
heat map, the spots with increased expression are indicated in
red, and the spots with decreased expression are indicated in
green. As indicated in the tree diagram and the heat map, the
patterns of protein expression were similar at geldanamycin
concentrations greater than 0.5 mM.
To simplify the statistical evaluation of the 2D-DIGE experi-
ments, the spots that were modified significantly between
groups were typically selected using the ANOVA test and aChemistry & Biology 17,volume ratio filter of no less than 2-fold for three biological repli-
cates per group (Karp and Lilley, 2005). Using these parameters,
17 spots were selected and a similar result for the cluster
analysis was obtained (data not shown).
HSP70 and HSP27 have been reported to be upregulated in
HSP90 inhibitor-treated cells (Maloney et al., 2007; McCollum
et al., 2006). To classify test compounds using proteomic
profiling, the identity of each protein spot is not necessary;
however, it is important to confirm whether a proteomic change
of geldanamycin-treated cells matches that in previously
reported results. Peptide mass fingerprinting identified 20 spots
out of the total number of spots that had been significantly
affected by the treatment with geldanamycin and other
compounds (Tables S2 and S3). The application of the ANOVA
test selected 15 out of 20 spots and the mean ratios between
control and inhibitor-treated cells were tabulated (Table 1).
Spots 1114 and 1127, which were identified as heat shock 70
kDa protein 1 (HSP70, HSPA1B), were upregulated more than
7-fold when compared with control. At 0.05 mM geldanamycin,
HSP70 upregulation was also detected, but the magnitude of
increase was lower compared with higher concentrations. The
expression level of spot 2382, identified as heat shock protein
b-1 (HSP27, HSPB1), also reached a plateau, as did HSP70. By
western blot, bothHSP70 andHSP27were upregulated to similar
extents at concentrations greater than 0.05 mM (Figure 1C).
The upregulation of mitochondrial heat shock proteins
(HSP9B, HSPD1) and protein disulfide isomerase and downre-
gulation of eukaryotic elongation factor 2 (EEF2), fascin
(FSCN1), adenylyl cyclase-associated protein 1 (CAP1), and
aldo-keto reductase family 1 member C2 (AKR1C2) were
observed in geldanamycin-treated HeLa cells. It is very impor-
tant to note that the concentration corresponding to the IC50 in
the WST-8 assay is insufficient to induce any obvious changes
in the proteomic analysis. It is more reasonable to use concen-
trations at which cell growth is nearly completely inhibited.
When the cells were exposed to 0.5 mM geldanamycin, the
amount of HSP70 increased in a time-dependent manner and
reached a plateau after 18 hr (Figures 1D and 1E). Because
long incubation with test compounds may be associated with
secondary effects such as apoptosis, we purposely avoided
long exposures. Instead, we performed a subsequent proteomic
analysis of HeLa cells after 18 hr exposure to a test compound.
Radicicol (2) is another HSP90 inhibitor that structurally differs
from geldanamycin (1). The expression patterns between radici-
col- and geldanamycin-treated cells were compared by 2D-
DIGE. Similar responses were observed between geldanamycin-
and radicicol-treated cells (Figure 1B; Table 2). HSP70 (1114 and
1127), HSP27 (2372 and 2382), and 78 kDa glucose-regulated
protein (GRP78, HSPA5; 972 and 983) increased during both
treatments (Table 2). The spots representing eukaryotic elonga-
tion factor 2, fascin, and adenylyl cyclase-associated protein
1 were downregulated during both treatments. These results
strongly suggest that compounds inhibiting the same molecular
target generate similar proteomic profiles.
Proteomic Analysis of HeLa Cells Treated with
Compounds of Known Mechanisms of Action
To compare proteomic patterns in HeLa cells treated with
compounds whose targets are known, well-characterized460–470, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 461
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Figure 1. Dose- and Time-Dependent Effects of Geldanamycin and Radicicol on HeLa Cells
(A) Geldanamycin or radicicol was added at the indicated concentrations and incubated for 48 hr. Cell number was measured by WST-8 assay, as described in
Experimental Procedures. Error bars represent SD (n = 3).
(B) HeLa cells treatedwith a compound at the indicated concentrations or with DMSO for 18 hr were analyzed by 2D-DIGE. Hierarchical clusteringwas performed.
Red, upregulated; green, downregulated. The spots identified by peptide mass fingerprinting (PMF) (Table S2) are indicated by an arrow, and the master number
and gene name are shown.
(C) Cell lysates incubated for 18 hr with designated concentrations of geldanamycin or radicicol were analyzed by western blot following SDS-PAGE using anti-
HSP70, anti-HSP27, or anti-tubulin.
(D) HeLa cells were incubated in the presence of 0.5 mM geldanamycin for the indicated times and analyzed by 2D DIGE. Using the data of 91 spots selected as
described in Experimental Procedures, hierarchical clustering was performed. The spots designated by the arrows are the spots (1114 and 1127) identified as
HSP70 by PMF.
(E) Mean ratios of spots 1114 and 1127, determined in (D), were plotted. Error bars represent SD (n = 3).
Chemistry & Biology
Proteomic Profiling for Compound Classificationchemical entities were selected for proteomic analysis (Table 2).
Based on experience with geldanamycin, the proteomic analysis
of above-mentioned compounds was performed at concentra-462 Chemistry & Biology 17, 460–470, May 28, 2010 ª2010 Elseviertions higher than their respective IC50 values. Their growth inhib-
itory effects were determined byWST-8 assay and are presented
as IC50 values in Table 2. The concentrations used for theLtd All rights reserved
Table 1. Expression Data of Identified Spots in HeLa Cells Treated with Geldanamycin or Radicicol
Compounds
Master Number of Spots and Gene Name of Identified Proteins
673 713 714 971 983 998 1114 1127 1295 1429 1484 1579 2014 2372 2382
HSP90AB1 EEF2 EEF2 HSPA5 HSPA5 HSPA9B HSPA1B HSPA1B HSPD1 CAP1 FSCN1 PDIA6 AKR1C2 HSPB1 HSPB1
Geldanamycin
0.005 mM
1.02 0.97 0.95 1.03 1.01 0.95 1.05 1.10 1.02 0.96 0.97 1.04 0.95 1.04 0.98
Geldanamycin
0.05 mM
0.97 0.93 0.95 1.07 1.04 1.03 2.74** 3.40** 1.19* 0.96 0.96 1.02 0.91* 1.41* 1.43**
Geldanamycin
0.5 mM
1.29** 0.71** 0.63** 2.26** 1.29* 1.39** 7.22** 8.94** 1.75** 0.61** 0.71** 1.19** 0.66** 2.38** 1.90**
Geldanamycin
5 mM
1.31** 0.66** 0.59** 5.90** 2.70** 1.31** 7.33** 9.20** 1.62** 0.39** 0.72** 1.44** 0.69** 2.48** 1.82**
Geldanamycin
10 mM
1.41** 0.70** 0.55** 5.72** 2.71** 1.41** 8.05** 9.26** 1.64** 0.40** 0.71** 1.42** 0.66** 2.64** 1.75**
Radicicol
10 mM
1.19* 0.82* 0.72** 2.60** 1.28* 1.28* 7.43** 9.39** 1.34** 0.55** 0.75** 1.07 1.06 2.11** 1.65**
The mean ratios of identified spots between control and compound-treated cells are listed. Non-repeated-measures ANOVA and Dunnett’s test for
post hoc analysis were performed. Asterisks indicate significant differences from respective controls (*p < 0.05, **p < 0.01).
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Proteomic Profiling for Compound Classificationexposure of HeLa cells during proteomic profiling experiments
were those inhibiting cell growth by 80% or more (Table 2).
As previously indicated, proteomic analyses of HeLa cells
were performed after an 18 hr exposure to a test compound.
Because the master gel of geldanamycin-treated cells from the
previous experiment (Figure 2A) was used as the template, the
numbering of the spots remained the same in all experiments.
Three hundred eighteen spots in the 2DE gel were matched on
all gel images and quantified by 2D-DIGE software; 298 of
them were selected by ANOVA (p < 0.01) and Dunnett’s test
(p < 0.01) (see Table S4). The data were calculated and visualized
by cluster analysis programs (Figure 2B); the mean ratio of theTable 2. Compounds for Proteomic Analysis by 2D-DIGE
Compounds Target IC50 (mM)
a
Actinomycin D RNA synthesis 0.0022
Bafilomycin A1 V-ATPase 0.0035
Brefeldin A Protein transport 0.023
Concanamycin A V-ATPase 0.002
Cycloheximide Protein synthesis 0.17
Cytochalasin D Actin 0.32
Daunomycin DNA synthesis 0.034
Etoposide Topoisomerase II 3
Geldanamycin HSP90 0.18
ICRF-193 Topoisomerase II 2
Jasplakinolide Actin 0.038
LY294002 PI3 kinase 12
MG-132 Proteasome 0.24
Nocodazole Tubulin 0.027
Okadaic acid Phosphatase 0.014
Radicicol HSP90 2.1
Staurosporine Protein kinase 0.03
Tunicamycin N-linked oligosaccharide synthesis 0.27
Vinblastine Tubulin 0.0031
a The 50% inhibitory concentration of HeLa cell growth.
bConcentrations used for proteome analysis.
Chemistry & Biology 17,identified spots and the results of statistical analysis are listed
in Table S4.
As indicated in the tree diagram (Figure 2B), the inhibitors of
V-ATPase (bafilomycin A1 and concanamycin A), tubulin (noco-
dazole and vinblastine), and actin (cytochalasin D and jasplaki-
nolide) were classified into separate clusters. The spots that
changed significantly between groups were selected using
ANOVA and a volume ratio filter of no less than 2-fold (Karp
and Lilley, 2005), yielding 47 spots and leading to a similar result
of cluster analysis (data not shown).
We also noticed that MG-132, a proteasome inhibitor, gener-
ated a similar pattern as the HSP90 inhibitors did. The amount ofConcentration (mM)b References
0.015 Sobell, 1985
0.01 Bowman et al., 1988
0.05 Klausner et al., 1992
0.005 Huss et al., 2002
2 Obrig et al., 1971
1 Cooper, 1987
1 Aubel-Sadron and Londos-Gagliardi, 1984
50 Liu, 1989
0.5 Whitesell et al., 1994
50 Roca et al., 1994
0.1 Bubb et al., 1994
42 Vlahos et al., 1994
1 Lee and Goldberg, 1998
5 Lin and Hamel, 1981
0.03 Bialojan and Takai, 1988
10 Schulte et al., 1998
0.3 Ru¨egg and Burgess, 1989
5 Takatsuki et al., 1971
0.01 Rai and Wolff, 1998
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Figure 2. Clustering of Well-Characterized Compounds and Iejimalides by Proteomic Analysis of HeLa Cells
(A) HeLa cells treated with compounds listed in Table 2 for 18 hr were analyzed by 2DDIGE. The position of each spot is designated by a red circle, and themaster
number of the spot is marked.
(B) Hierarchical clustering was performed. The identified spots (Table 3) are designated by arrows.
(C) HeLa cells were treated with 30 nM iejimalides A and B. The quantitative data were combined with the data of 19 well-characterized compounds and hier-
archical clustering was performed.
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Proteomic Profiling for Compound Classificationprotein in the HSP70 spots (spots 1114 and 1127) also increased
in MG-132-treated cells, as did those observed in geldanamy-
cin- and radicicol-treated cells (Table 3). In contrast, HSP27
showed an aberrant pattern. Although HSP90 inhibitors
increased in amount in spots 2372 and 2382, which were identi-464 Chemistry & Biology 17, 460–470, May 28, 2010 ª2010 Elsevierfied as HSP27,MG-132 treatment increased only in spot number
2372.
Other noteworthy changes were as follows: (1) the inhibitors of
actin, cytochalasin D, and jasplakinolide increased the amount
of actin (spots 1758 and 1767); (2) tunicamycin increased inLtd All rights reserved
Table 3. Expression Data of Identified Spots on HeLa Cells Treated with Well-Characterized Compounds
Compounds
Master Number of Spots and Gene Name of Identified Proteins
713 714 970 983 987 998 1114 1127 1227 1295 1429 1484 1579 1758 1767 2014 2372 2382
EEF2 EEF2 LMNA HSPA5 LMNA HSPA9B HSPA1B HSPA1B HNRNPK HSPD1 CAP1 FSCN1 PDIA6 ACTG1/ACTB ACTG1 AKRLC2 HSPB1 HSPB1
Okadaic acid 0.97 0.79* 0.86 1.10 0.97 1.12 1.30 1.22 0.88 1.12 0.61** 1.05 1.03 0.92 1.05 1.12* 2.31** 0.77**
Actinomycin D 1.12 1.12 1.16 1.01 1.29** 0.96 1.02 1.12 0.91 0.99 0.74** 1.12 1.06 0.99 1.04 1.11 1.83** 1.08
Daunomycin 1.18 1.08 1.18 0.97 1.59** 0.92 1.02 1.06 0.90 0.93 0.97 0.92 1.09 0.82 0.91 0.96 1.63** 1.03
Etoposide 1.05 1.05 1.09 1.04 1.19 1.05 1.14 1.16 1.02 1.03 1.06 0.92 1.06 0.99 0.95 0.86* 1.81** 0.93
Vinblastine 0.96 1.01 0.49** 0.83* 0.49** 1.09 1.51 1.10 0.47** 0.97 0.49** 1.04 0.95 1.19 1.32** 1.05 1.61** 0.91
Nocodazole 0.95 0.87 0.41** 0.86 0.59** 1.12 1.40 1.04 0.48** 0.92 0.43** 1.00 0.96 1.20 1.61** 0.81** 2.11** 0.89
ICRF-193 0.93 0.90 0.60** 0.87 0.59** 1.14 1.38 1.28 0.69** 1.01 0.62** 0.93 1.02 1.04 1.17 0.94 1.58** 1.04
LY294002 1.06 0.87 0.88 1.08 1.14 1.08 1.00 0.87 0.63** 0.93 0.62** 0.71** 1.12 0.96 1.11 0.89 2.08** 0.99
Staurosporine 0.90 0.67** 0.28** 1.71** 0.87 1.40** 1.07 0.80 0.31** 1.42** 0.33** 0.58** 1.07 0.97 1.42** 1.09 1.03 2.30**
Jasplakinolide 1.08 0.94 0.84 0.88 0.94 0.98 1.09 0.89 0.90 0.80** 1.22** 1.06 0.97 1.54** 1.93** 0.83** 1.04 1.07
Cytochalasin D 1.07 0.80* 0.90 0.83* 1.04 1.05 1.10 0.74 0.86 0.79** 1.10* 0.77** 0.94 1.25* 1.86** 0.75** 1.20 0.80**
Brefeldin A 1.07 0.98 0.91 1.25** 0.99 1.01 0.94 0.93 0.89 0.78** 0.97 0.87* 0.96 0.94 0.96 0.95 1.55** 0.88
Cycloheximide 1.21* 1.09 0.87 0.70** 1.05 0.90 0.90 0.78 0.82** 0.79** 0.95 0.92 0.90 0.96 1.15 0.90 1.88** 0.85
Tunicamycin 1.19* 1.10 0.72** 4.62** 0.85 1.02 0.94 0.80 0.75** 0.82** 0.81** 0.93 1.11 1.13 1.22 1.04 1.67** 0.86*
Bafilomycin A1 0.79* 0.71** 1.38** 1.31** 1.71** 1.25** 0.93 0.85 1.23** 1.23** 0.62** 0.61** 1.19** 0.84 1.01 0.68** 2.25** 0.99
Concanamycin A 0.85 0.74** 1.23* 1.02 1.50** 1.04 0.91 0.81 1.07 0.99 0.72** 0.76** 0.99 0.84 0.99 0.67** 2.03** 0.85**
MG-132 0.92 0.82* 0.91 1.40** 1.10 1.10 7.18** 6.84** 0.78** 1.10 0.90* 0.69** 1.04 0.93 0.98 0.84** 4.01** 0.93
Radicicol 0.82 0.72** 0.75** 1.28** 0.70** 1.28** 7.43** 9.39** 0.88 1.34** 0.55** 0.75** 1.07 0.95 1.18 1.06 2.11** 1.65**
Geldanamycin 0.71** 0.63** 1.02 1.29** 0.95 1.39** 7.22** 8.94** 1.09 1.75** 0.61** 0.71** 1.19** 1.04 1.08 0.66** 2.38** 1.90**
The mean ratios of identified spots between control and compound-treated cells are listed. Non-repeated-measures ANOVA and Dunnett’s test for post hoc analysis were performed. Asterisks
indicate significant differences from respective controls (*p < 0.05, ** p < 0.01). The order of compounds follows that in Figure 2B.
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Figure 3. Differential Phenotypes of HeLa Cells Treated with ICRF-
193 and Etoposide by Flow Cytometry
The distribution of cellular DNA content of asynchronous HeLa cells treated
with ICRF-193 or etoposide was determined by flow cytometry. HeLa cells
were treated with the indicated concentrations of ICRF-193 (A) or etoposide
(B) for 48 hr. In a time course experiment, HeLa cells were treated with
10 mM ICRF-193 (C) or etoposide (D) for the indicated times.
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Proteomic Profiling for Compound Classificationspot 983, identified as GRP78, 4.6-fold compared with control;
(3) ICRF-193 and antimicrotubular agents such as nocodazole
and vinblastine decreased the amount of lamin (spots 970 and
978), in consequence forming one cluster; and (4) the potent
protein kinase inhibitor staurosporine downsized the spots 714
(EEF2), 970 (LMNA), 1227 (HNRNPK), 1429 (CAP1), and 1484
(FSCN1), whereas expanding the spots 983 (HSPA5), 998
(HSPA9B), 1295 (HSPD1), 1767 (ACTG1), and 2382 (HSPB1).
Iejimalides, 24-membered macrolides, were originally isolated
from marine tunicate as potent antitumor compounds (Nozawa
et al., 2006). We recently found that iejimalides inhibited
V-ATPase (Kazami et al., 2006). We have analyzed HeLa cells
treated with iejimalide A (3) or iejimalide B (4) at 30 nM by
2D-DIGE. We combined the proteome data from iejimalide-
treated HeLa and compared them with the proteomic profiles
generated by the treatment of HeLa cells with 19 well-character-
ized compounds. Iejimalide A (3) andB (4) were clustered into the
same tree as the other V-ATPase inhibitors (e.g., bafilomycin A1466 Chemistry & Biology 17, 460–470, May 28, 2010 ª2010 Elsevier[5] and concanamycin A [6]) (Figure 2C). Recently, it was re-
ported that iejimalides affect actin depolymerization (Fu¨rstner
et al., 2007); however, iejimalides A and B did not match the
cluster representing actin inhibitors. These results indicate that
the primary target of iejimalides in HeLa cells is V-ATPase, at
least at the concentration used in our experimental setting.
Flow Cytometry of HeLa Cells Treated with ICRF-193
and Etoposide
The proteomic analysis of HeLa cells treated with the two struc-
turally different inhibitors of topoisomerase II (topo II), ICRF-193
(7) and etoposide (8), revealed significant differences; the two
compounds were not able to form a single cluster (Figure 2B).
To confirm this finding, we measured the distribution of cellular
DNA in HeLa cells by flow cytometry after treating asynchronous
HeLa cells with varying concentrations of ICRF-193 or etoposide
for 48 hr.
The basic amount of DNA in a haploid nucleus is given the
value C. In the absence of inhibitors, we typically observed two
peaks, corresponding to cell populations with 2C and 4C DNA
content. The treatment of HeLa cells with ICRF-193 resulted in
decreasing the height of the 2C peaks at concentrations higher
than 1 mM, while the 4C population increased (Figure 3A). On
the other hand, etoposide used at concentrations higher than
1 mM also increased the 4C peaks, but without any obvious
accumulation of the peaks containing 8C DNA, in contrast to
the effect of ICRF-193 (Figure 3B).
The kinetics of the shifts from the diploid to tetraploid DNA
cellular contents was also studied in a time-dependent fashion,
using equimolar concentrations of 10 mM for both test
compounds. ICRF-193 induced a gradual accumulation of 4C
population up to 18 hr, and then the generation of polyploidy
(8C) in HeLa cells was observed (Figure 3C) beyond that time
point.
Etoposide was not able to induce polyploidy in HeLa cells,
even during a 72 h exposure (Figure 3D). Despite the presence
of a common mechanism of action (topo II inhibition), the final
biological effects were different, and the two compounds were
clustered into a different cluster in our proteomic analysis.
DISCUSSION
In this study, we have performed a proteomic analysis of HeLa
cancer cells treated with well-characterized anticancer agents
using a 2D-DIGE system. The target proteins of these
compounds are known at the cellular level and represent targets
for cancer therapeutics such as the proteasome and microtu-
bules. Each compound induced a characteristic proteomic
pattern, and hierarchical clustering exactly classified the
compounds according to their respective targets, such as
HSP90, tubulin, and V-ATPase (Figure 2B).
Topo II inhibitors are still good candidates for molecular tar-
geted drugs in cancer therapy. Topo II as a single target can
be inhibited by two distinct mechanisms. One is exercised
by a catalytic site inhibition, resulting in the formation of
a noncleavable complex and is characteristic for ICRF-193,
a topo II inhibitor (7) (Roca et al., 1994; Tanabe et al., 1991).
The other mechanism involves the stabilization of a DNA-cleav-
able complex, which further leads to double-strand DNA breaksLtd All rights reserved
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Proteomic Profiling for Compound Classificationand damage; etoposide (8), a topo II poison, plays an essential
role in this mechanism (Liu, 1989). As reported by Ishida et al.,
etoposide blocked the progression of cells to M phase, whereas
ICRF-193 only delayed the transition from S to M phase and
induced polyploidization in HeLa cells (Ishida et al., 1994).
Thus, both compounds are topo II inhibitors but act through
disparate mechanisms (Andoh and Ishida, 1998). Their proteo-
mic phenotypes differed and did not fall into the same cluster.
Moreover, their cellular phenotypes, as determined by the anal-
ysis of cellular DNA distribution (Figure 3), differed as well. One
may conclude that such compounds can be classified into
different clusters from a proteomic point of view, despite
exercising their biological activity through the same molecular
target, or their exact mechanism of action may be revised. An
inability to share a common cluster might be caused by an
excessive off-target effect. To clarify this matter, it seems impor-
tant to know which mechanism determines anticancer activity
against a particular type of cancer or contributes mainly to
toxicity. Gathering more data will be of great importance in the
evaluation of undesired effects as well.
So far, our proteomic profiling of mechanisms of action of
anticancer agents appeared to be helpful in the identification of
the mode of action of iejimalides, newly isolated natural prod-
ucts, as being inhibitors of V-ATPase (Figure 2C). The compar-
ison of the proteomes of cells treated with a newly isolated
compound versus well-characterized compounds can lead to
a testable hypothesis on general mechanisms of action as in
the case of other profiling approaches such as the genetic one.
Despite recent enthusiasm, one may anticipate certain limita-
tions of our proteome profiling system. To name a few, the
following factors may become obstacles in the system. (1) The
suspected target for a test compound is not expressed or is
not functional (mutation, single-nucleotide polymorphism) in
HeLa cells. (2) The suspected target was not validated yet by
known standards. (3) The changes induced in the proteomic
profile by a test compound are not sufficiently distinct due to
the appearance of a limited number of spots in 2D gels. (4) The
presence of several molecular targets may complicate the anal-
ysis; therefore, an interpretation of the data will have to be made
with great caution.
Our proteomic analysis matched methyl-gerfelin with two
V-ATPase inhibitors; however, its biological effects in a cell
system (upregulation of pH) (Figure S1) were not confirmed.
Our newly developed technology of a small-molecule affinity
matrix revealed a strong interaction with glyoxalase I, suppos-
edly a direct target molecule (Kawatani et al., 2008). The lack
of standards for glyoxalase I inhibitors in proteomic analysis
led to clustering with V-ATPase inhibitors. Therefore, the expan-
sion of the system by a variety of compounds with increased
precision and accuracy in classifying compounds into groups
will lead to a well-established mechanism of action. Compounds
not matching any known mechanisms may be considered as
probes for searching molecular targets not yet identified.
The case of jasplakinolide and cytochalasin D may well illus-
trate some of the obstacles, as both compounds affect actin
by inhibiting its depolymerization (Bubb et al., 1994) and poly-
merization (Cooper, 1987), respectively. Although their effects
on actin are opposed, both compounds increased the levels of
actin and were included in the same cluster in this experiment.Chemistry & Biology 17,However, we noted the presence of several unidentified spots
that did not correlate to these two compounds. Further investi-
gation should clarify differences between polymerizing and
depolymerizing effects of these two inhibitors with the applica-
tion of proteomic analysis.
2DE-based proteomic analysis is generally a time-consuming
process during the initial stage of system development, because
the identification of almost all protein spots is essential. Once
this stage is completed and a database is created, one can
analyze the proteomic profiles of many chemical entities by
comparing them with those contained in the database, without
the necessity of additional protein spot identification. This is
a huge advantage of this technique. Nevertheless, in the case
of dramatic changes in expression levels among spots not
yet identified, the characterization of these spots will be very
informative in target identification, or at least these compound-
specific spots may serve as an important marker of biological
activity. Agents inducing microtubule depolymerization may
serve as an illustration of where a compound does not directly
cause the modification of a protein spot, and is rather an artifact
related to its primary mechanism of action. More specifically,
antimicrotubular agents cause cell-cycle arrest in M phase, pre-
venting cell division due to the lackmitotic spindle formation, and
the nuclear envelope remains intact. Under normal conditions
the envelope is broken down and its component, lamin, is
released (Parnaik, 2008). The release of lamin is decreased after
the exposure of the cells to antimicrotubular agents (Table 3) and
may serve as a marker of compound’s effectiveness, albeit not
being a target.
The treatment of HeLa cells with MG-132 increased the
expression of HSP70, thus confirming already reported
phenomena (Kawazoe et al., 1998), and the cluster analysis
tree positioned this compound close to the group of HSP90
inhibitors. However, slight differences were observed, namely,
HSP90 inhibitors increased both spots of HSP27 (2372 and
2382), whereas MG-132 increased only spot 2372. Because
HSP27 has been reported to enhance proteasome-dependent
protein degradation (Parcellier et al., 2003, 2006), this result
may suggest the presence of at least two forms of HSP27, one
of which is probably involved in proteasome-dependent protein
degradation. Based on these results, we propose that the
expression levels of HSP27 spots may determine the classifica-
tion of compounds either to the HSP90 inhibitor or to the protea-
some inhibitor class of compounds. Particularly, the expression
ratio of HSP70 and HSP27 spots will play the role of differenti-
ating marker for either class.
So far, we have examined only 19 compounds, reaching an
ability to classify the compounds according to their mechanism
of action. The expansion of proteomic profiling by the other types
of compounds with different modes of action will make the
system fully operational for the prediction of biological activity
of newly discovered natural products or synthetic compounds.
Already, we have been able to classify a newly synthesized deriv-
ative of a natural product with an unknown mechanism of action
as an inhibitor of topoisomerase II (data not shown). For that
purpose, the extensive process of system validation using the
chemical library of NPDepo (Tomiki et al., 2006) is under way.
Because the assay is primarily based upon only one cancer
cell line, it is reasonable to include other cell lines, especially460–470, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 467
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observed. As the natural consequence of the recent promising
results, there is the need to include a protein interaction map
that should enforce the discovery of new target molecules.
One may easily indicate a protein spot which may become
a marker; however, one should explore the path from the marker
up to the protein responsible for that change. Then the protein
may be claimed to be a target or, in other words, the object of
a primary attack by an active substance.
In summary, proteomic profiling based on 2D-DIGE is an
important supplement to other multidimensional phenotypic
profilings and its capacity may be extended by the introduction
of different pathological phenotypes represented by cancer
cells, leading, for example, to identification of specific biomole-
cules as well.
SIGNIFICANCE
New natural compounds, possessing important biological
activity, have been subjected to extensive and time-
consuming processes to clarify main mechanisms of action.
In order to reduce the time for target identification, we set up
a faster method based on 2D-PAGE characteristic proteo-
mic patterns of HeLa cells treated with various compounds.
Compounds such as geldanamycin and radicicol, represent-
ing diverse structures but sharing a common target, were
classified in the same tree by cluster analysis. Iejimalides
A and B were reported to affect depolymerization of actin;
however, these were not clustered together with actin inhib-
itors but instead were clustered into a group of V-ATPase
inhibitors, as has been confirmed by the direct inhibitory
effect of iejimalides A and B on V-ATPase (Kazami et al.,
2006). Furthermore, when different types of topo II inhibitors,
etoposide and ICRF-193, which are known as a topo II
poison and a catalytic inhibitor, respectively, were analyzed
by the system, the compounds were clustered into different
trees. This indicates a power of the system that discrimi-
nates compounds by mechanism of action. The expansion
of the database of proteomic profiling by a 2D-PAGE
assay will aid the characterization of numerous natural
compounds in many aspects, such as mechanism of action,
off-target effects, biomarking, and yet unknown target iden-
tification.
EXPERIMENTAL PROCEDURES
Materials
Iejimalides A and B were obtained from Dr. Jun’ichi Kobayashi of Hokkaido
University. Actinomycin D, brefeldin A, concanamycin A, cycloheximide, cyto-
chalasin D, geldanamycin, radicicol, staurosporine, and etoposide were
provided by the NPDepo (RIKEN Natural Products Depository; http://www.
npd.riken.jp/npd). Bafilomycin A1, daunomycin, and tunicamycin were
purchased from Wako Pure Chemical Industries. Okadaic acid and nocoda-
zole were purchased from Sigma. Jasplakinolide, LY294002, MG-132, and
vinblastine were from Calbiochem. ICRF-193 was from Funakoshi.
All compounds were dissolved in dimethyl sulfoxide (DMSO) and stocked at
20C. Monoclonal anti-HSP70 (clone C92F3A-5) and monoclonal anti-
HSP27 (clone G3.1) were purchased from Stressgen Biotechnologies. Mono-
clonal anti-a-tubulin (clone DM1A) was purchased from Sigma. The reagents
for western blotting were purchased from Thermo Scientific. All reagents
were reagent grade.468 Chemistry & Biology 17, 460–470, May 28, 2010 ª2010 ElsevierCell Culture
HeLa cells were cultured in Dulbecco’s modified Eagle’s medium, supple-
mented with 10% fetal bovine serum, at 37C in a humidified CO2 incubator
(5% CO2/95% air).
Cell Growth Assay
HeLa cells were seeded at 23 103 cells per well in a 96-well culture plate and
incubated overnight; test compounds were added to the medium at various
concentrations. After 48 hr, cell number was determined using Cell Count
Reagent SF (Nakalai Tesuque) according to the manufacturer’s protocol.
Briefly, 10 ml of WST-8 solution (mixture of WST-8 and 1-methoxy-5-methyl-
phenazinium methylsulfate) was added to the wells and incubated for 2 hr,
and cell number was assessed by measuring the absorbance at 450 nm on
a microplate reader (Bio-Rad).
Preparation of Cell Lysates for Proteomic Analysis
HeLa cells (33 105 cells) were seeded on a culture dish (35 mmdiameter) con-
taining 3 ml of medium and incubated overnight. Each assay was done in trip-
licate. The cells were exposed for 18 hr to the designated concentrations of
test compounds. Cells were washed three timeswith ice-cold phosphate-buff-
ered saline (PBS), removed by a rubber policeman, and collected by centrifu-
gation at 4000 rpm for 3 min at 4C in a microcentrifuge (Kubota 3700).
After being washed once with PBS, cells were suspended in sample buffer
(7 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris, buffered to pH 8.5) for 2D-
DIGE and disrupted with a TOMY UR-20P sonicator. Cell lysates were treated
with 1.25 U/ml benzonase (Merck) for 60 min on ice and centrifuged at 12,000
rpm for 3 min at 4C. Supernatants were stocked at 80C until use.
Labeling of Cell Lysates and 2DE
Protein concentration was determined by the Bradford procedure using
a protein assay kit from Bio-Rad. Fifty micrograms of protein was labeled
with 200 pmol of CyDye DIGE Fluor minimal dyes (GE Healthcare) according
to the manufacturer’s instructions (Cy3 and Cy5 for samples and Cy2 for
internal control, consisting of equal parts of all samples in an experiment).
Samples were applied by rehydration onto immobilized pH gradient (IPG)
strips (24 cm, pH 3–10, nonlinear gradient; GE Healthcare) and subjected to
isoelectrofocusing in an IPGphor IEF system (GE Healthcare). Strips were
incubated in equilibration buffer (6 M urea, 30% glycerol, 2% SDS, 50 mM
Tris-HCl [pH 8.8]) containing 1% DTT for 15 min and then incubated in the
same buffer containing 2.5% iodoacetamide for 15 min. Strips were trans-
ferred to the tops of 10% polyacrylamide gels and electrophoresed overnight
in a DALT Twelve apparatus (GE Healthcare).
After electrophoresis, gels were scanned using a Typhoon 9400 imager at
100 dpi resolution (GEHealthcare). Gel analysis was performed using DeCyder
BVA 6.5 (GE Healthcare), a 2DE analysis software package, following the
manufacturer’s recommendations. The estimated number of spots for each
codetection was set to 3000.
Experimental Design and Data Processing for 2DE Profiling
To perform visual 2DE protein profiling of compound-treated HeLa cells,
experiments were divided into subsets. We used the spot number of the
master gel as the common master number for all of the experiments. The gel
that contained the most spots in the first experiment (analysis of HeLa cells
treated with various concentrations of geldanamycin) was chosen as the
master gel.
In a representative subset of experiments, we used three compounds and
DMSO. HeLa cells were treated with these solutions, and proteomic analysis
was performed. All samples of compound- and DMSO-treated cells were
prepared in triplicate. Equal parts of all samples in a subset of experiments
were labeled with Cy2 CyDye Fluor as an internal standard.
To match the common master numbers between subsets of experiments,
image files were imported into the project file, including the master gel, and
spot maps of the images were matched to the master gel image using the
BVA modules of DeCyder 6.5. More than 650 spots were usually matched in
all the analyzed gels of a subset. The volume of each spot was obtained as
a ratio of the Cy3- or Cy5-labeled sample compared with the corresponding
Cy2 signal of the internal standard. Then, the volume of each spot wasLtd All rights reserved
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DMSO-treated HeLa cells.
Normalized volume data in subsets of experiments were combined, and only
spots that did not lack data in any of the gels were selected. Subsequently, the
spots that showed significant changes after compound treatment were
selected by ANOVA (p < 0.01) and Dunnett’s test for post hoc analysis. For
cluster analysis, the normalized volumes were calculated using the means of
uncentered correlation with centroid linkage using Cluster 3.0 (de Hoon
et al., 2004) and visualized using Java Treeview (Saldanha, 2004).
Statistical calculations, such as nonrepeated-measures ANOVA and Dun-
nett’s test for post hoc analysis (Sheskin, 2000), were performed using Micro-
soft Excel with a statistical macro (ystat2006; Igaku Tosho Shuppan) and
R version 2.9.2 (http://cran.r-project.org).
Western Blotting
Cell lysates were resolved by 10% SDS-PAGE and transferred to PVDF
membranes. Membranes were blocked with 5% nonfat dried milk in TBS-T
buffer (10 mM Tris-HCl [pH 8.0], 150 mM NaCl, 0.05% Tween 20), followed
by incubation with primary antibody (1:1000 dilution) in TBS-T. The detection
was performed using horseradish peroxidase-labeled secondary antibodies
(1:1000 dilution) and enhanced chemiluminescence detection reagent. The
expression of tubulin was also measured and used as an internal control.
Flow Cytometry
Cells were treated with 0.25% trypsin for 5 min to remove them from the dish,
washed with PBS, fixed in cold PBS containing 70% (v/v) ethanol, and stored
at20C overnight. Then, the cells were washed with PBS and incubated with
a DNA-staining solution containing 50 mg/ml propidium iodide (Sigma) and
2 mg/ml RNase A at 4C for 30 min. Total fluorescence intensities were deter-
mined by quantitative flow cytometry with Cytomics FC500 (Beckman
Coulter).
SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure and four tables and can be
found with this article online at doi:10.1016/j.chembiol.2010.03.016.
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